Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses PSNL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named PSNL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Hall | $618,000 | $0 | $853,050 | $1,784,728 | $247,200 | $0 | $3,000 | $3,505,978 |
| Chief Executive Officer and Director | ||||||||
| Aaron Tachibana | 545,900 | 0 | 272,250 | 656,150 | 131,000 | 0 | 3,000 | 1,608,300 |
| Chief Financial Officer and Chief Operating Officer | ||||||||
| Richard Chen | 530,450 | 0 | 272,250 | 656,150 | 127,300 | 0 | 3,000 | 1,589,150 |
| President, Executive Vice President, Research and Development and Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Christopher Hall | $3,505,978 | $1,535,960 | — | +1,970,018 |
| Aaron Tachibana | 1,608,300 | 1,011,594 | — | +596,706 |
| Richard Chen | 1,589,150 | 989,394 | — | +599,756 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christopher Hall | RSU | 56,250 | — | $447,750 |
| Christopher Hall | PSU | 117,500 | — | 935,300 |
| Aaron Tachibana | PSU | 37,500 | — | 298,500 |
| Richard Chen | PSU | 37,500 | — | 298,500 |
| Christopher Hall | Option | 57,292 | 2.67 | — |
| Christopher Hall | Option | 33,334 | 2.76 | — |
| Christopher Hall | Option | 166,667 | 1.61 | — |
| Christopher Hall | Option | 510,000 | 3.63 | — |
| Aaron Tachibana | Option | 37,500 | 2.76 | — |
| Aaron Tachibana | Option | 72,917 | 1.61 | — |
| Aaron Tachibana | Option | 187,500 | 3.63 | — |
| Richard Chen | Option | 20,834 | 2.76 | — |
| Richard Chen | Option | 72,917 | 1.61 | — |
| Richard Chen | Option | 187,500 | 3.63 | — |
Personalis maintains a pay-for-performance compensation philosophy designed to incentivize management to drive company performance and increase stockholder value. The program aims to attract, retain, and motivate top-quality executives by aligning their interests with those of stockholders through a significant portion of at-risk, performance-based compensation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-12 | 75,549,455 | 384,918 | 78,724 | 99.49% | Passed |
| 2025 | 2025-05-16 | 56,604,799 | 2,244,133 | 38,126 | 96.19% | Passed |
| 2024 | 2024-05-17 | 25,393,708 | 634,656 | 225,652 | 97.56% | Passed |
| 2023 | 2023-05-17 | 28,615,039 | 475,452 | 197,717 | 98.37% | Passed |
| 2022 | 2022-05-17 | 22,642,573 | 2,376,303 | 39,867 | 90.5% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-12 | 99.49%a |
| 2025 | 2025-05-16 | 96.19%b |
| 2024 | 2024-05-17 | 97.56%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Karin EasthamIndependent · Board Chair · Nominating and Corporate Governance (Chair) | $120,000 | $0 | $177,225 | — | — | $297,225 |
| Olivia K. BloomIndependent · Audit (Chair) | 67,500 | 0 | 177,225 | — | — | 244,725 |
| A. Blaine BowmanIndependent · Compensation (Chair) | 65,000 | 0 | 177,225 | — | — | 242,225 |
| Woodrow Myers Jr., M.DIndependent · Compensation · Nominating and Corporate Governance | 52,500 | 0 | 177,225 | — | — | 229,725 |
| Lonnie ShoffIndependent · Audit · Compensation | 47,500 | 0 | 177,225 | — | — | 224,725 |
| Christopher HallEmployee director · Nominating and Corporate Governance | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $352,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $352,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Personalis names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Personalis.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | GeneDx | 2025 | Katherine Stueland | $715,869 | $11,738,600 | $0 | $1,075,500 | $13,547,219 |
| 2 | Standard BioTools | 2025 | Michael Egholm | 680,256 | 5,337,883 | 1,671,363 | 1,120,000 | 8,823,502 |
| 3 | Veracyte | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 4 | CareDx | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 5 | Castle Biosciences | 2025 | Derek Maetzold | 751,350 | 4,977,208 | 0 | 1,036,863 | 6,786,771 |
| 6 | Quanterix | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 7 | Pacific Biosciences of California | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 8 | OraSure Technologies | 2025 | Carrie Eglinton Manner | 721,000 | 3,394,188 | 0 | 173,040 | 4,292,228 |
| 9 | Personalis | 2025 | Christopher Hall | 618,000 | 853,050 | 1,784,728 | 247,200 | 3,505,978 |
| 10 | Codexis | 2025 | Alison Moore | 524,732 | 255,994 | 1,065,223 | 463,125 | 2,323,279 |
| 11 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| — | CytomX Therapeutics | — | — | — | — | — | — | not in coverage universe |
| — | Akoya Biosciences | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Personalis | not disclosed | Option 75 · PRSU 25 | not disclosed | Aon |
| Akoya Biosciences | not disclosed | not disclosed | not disclosed | not disclosed |
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| CareDx | 122% | RSU 70 · PSU 30 | No | Alpine Rewards |
| Castle Biosciences | 138% | RSU 50 · PSU 50 | No | AON (AON's Human Capital Solutions Practice, a division of AON plc) |
| Codexis | 95% | not disclosed | not disclosed | Pearl Meyer |
| CytomX Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| GeneDx | 150% | PSU 50 · RSU 50 | No | Pearl Meyer |
| OraSure Technologies | 24.0% | RSU 50 · PSU 50 | Yes — Relative TSR performance vs peer group | Pay Governance LLC |
| Pacific Biosciences of California | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Quanterix | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| Standard BioTools | 160% | not disclosed | not disclosed | Pearl Meyer |
| Veracyte | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Christopher Hall | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Executive Compensation”. As printed: 3,505,978. Filing ↗machine: r2 · c25 · span 489936–489945 |
| 2 | Section 01, Aaron Tachibana | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Executive Compensation”. As printed: 1,608,300. Filing ↗machine: r4 · c25 · span 509811–509820 |
| 3 | Section 01, Richard Chen | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Executive Compensation”. As printed: 1,589,150. Filing ↗machine: r6 · c25 · span 529710–529719 |
| 4 | Section 08, Karin Eastham | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 297,225. Filing ↗machine: span 1396233–1396240 |
| 5 | Section 08, Olivia K. Bloom | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 244,725. Filing ↗machine: span 1383695–1383702 |
| 6 | Section 08, A. Blaine Bowman | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 242,225. Filing ↗machine: span 1389965–1389972 |
| 7 | Section 08, Woodrow Myers Jr., M.D | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 229,725. Filing ↗machine: span 1402511–1402518 |
| 8 | Section 08, Lonnie Shoff | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 224,725. Filing ↗machine: span 1408777–1408784 |
| 9 | Section 08, Christopher Hall | DEF 14A | 2026-04-02 | 0001193125-26-140038 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 10 | Section 06, 2026 vote | Form 8-K | 2026-05-13 | 0001193125-26-221846 | Item 5.07 · say-on-pay result. As reported: 99.49% (votes for as printed: 75,549,455). Filing ↗ |
| 11 | Section 06, 2025 vote | Form 8-K | 2025-05-19 | 0000950170-25-074346 | Item 5.07 · say-on-pay result. As reported: 96.19% (votes for as printed: 56,604,799). Filing ↗ |
| 12 | Section 06, 2024 vote | Form 8-K | 2024-05-21 | 0000950170-24-062886 | Item 5.07 · say-on-pay result. As reported: 97.56% (votes for as printed: 25,393,708). Filing ↗ |
| 13 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 14 | Section 09b board cost (computed) | Computed | — | computed | Cash 352,500 + equity 0 + all other 0 = 352,500, summed across the director compensation table rows.machine: formula: Σ = 352,500 |
| 15 | GeneDx, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001818331-26-000030 | CEO total compensation as printed in GeneDx's own proxy. As printed: 13,547,219. Filing ↗machine: span 565318–565328 |
| 16 | Standard BioTools, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001140361-26-017100 | CEO total compensation as printed in Standard BioTools's own proxy. As printed: 8,823,502. Filing ↗machine: r2 · c22 · span 553256–553266 |
| 17 | Veracyte, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001384101-26-000021 | CEO total compensation as printed in Veracyte's own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422 |
| 18 | CareDx, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001217234-26-000028 | CEO total compensation as printed in CareDx's own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661 |
| 19 | Castle Biosciences, Section 10b CEO total | DEF 14A | 2026-04-08 | 0001628280-26-024166 | CEO total compensation as printed in Castle Biosciences's own proxy. As printed: 6,786,771. Filing ↗machine: r3 · c24 · span 933087–933096 |
| 20 | Quanterix, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001104659-26-048166 | CEO total compensation as printed in Quanterix's own proxy. As printed: 5,250,745. Filing ↗machine: t18 · r1 · c47 · span 503076–503085 |
| 21 | Pacific Biosciences of California, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001299130-26-000064 | CEO total compensation as printed in Pacific Biosciences of California's own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983 |
| 22 | OraSure Technologies, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001116463-26-000032 | CEO total compensation as printed in OraSure Technologies's own proxy. As printed: 4,292,228. Filing ↗machine: t152 · r2 · c21 · span 850376–850385 |
| 23 | Personalis (subject), Section 10b CEO total | DEF 14A | 2026-04-02 | 0001193125-26-140038 | CEO total compensation as printed in Personalis's own proxy. As printed: 3,505,978. Filing ↗machine: r2 · c25 · span 489936–489945 |
| 24 | Codexis, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186994 | CEO total compensation as printed in Codexis's own proxy. As printed: 2,323,279. Filing ↗machine: r2 · c27 · span 319928–319937 |
| 25 | Alector, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 26 | Section 10a, Castle Biosciences reciprocity | DEF 14A | — | 0001628280-26-024166 | Castle Biosciences's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 27 | Section 10a, Veracyte reciprocity | DEF 14A | — | 0001384101-26-000021 | Veracyte's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 28 | Section 10a, Standard BioTools reciprocity | DEF 14A | — | 0001140361-26-017100 | Standard BioTools's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 29 | Section 10a, GeneDx reciprocity | DEF 14A | — | 0001818331-26-000030 | GeneDx's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 30 | Section 10a, Alector reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 31 | Section 10a, Pacific Biosciences of California reciprocity | DEF 14A | — | 0001299130-26-000064 | Pacific Biosciences of California's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 32 | Section 10a, CareDx reciprocity | DEF 14A | — | 0001217234-26-000028 | CareDx's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |
| 33 | Section 10a, OraSure Technologies reciprocity | DEF 14A | — | 0001116463-26-000032 | OraSure Technologies names Personalis in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 34 | Section 10a, Quanterix reciprocity | DEF 14A | — | 0001104659-26-048166 | Quanterix's most recent proxy was read; its disclosed peer group does not include Personalis. Filing ↗ |